Welcome to our dedicated page for FOXO TECHNOLOGIES news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO TECHNOLOGIES stock.
FOXO Technologies Inc. operates healthcare-related subsidiaries that include a critical access acute care hospital, a behavioral health treatment business, a biotechnology subsidiary and Vector BioSource, a biospecimen and data sourcing provider for biotechnology, clinical research and pharmaceutical research customers.
Company news commonly covers clinical-capability additions at Big South Fork Medical Center, swing-bed and specialty-care arrangements, license and operating updates for Myrtle Recovery Centers, acquisition activity, capital-structure actions and trading-status developments for FOXO common stock on the OTC market.
FOXO Technologies (OTC: FOXOD/FOXO) announced that its subsidiary Vector BioSource has entered a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, a subsidiary of Grifols S.A. The asset purchase includes an upfront cash payment and a potential future earnout tied to the acquired centers achieving specified EBITDA targets in calendar years 2026, 2027 or 2028.
According to FOXO, based on historical data and management estimates, the transaction is expected to add over $10 million in net revenues during the first 12 months after closing from sales of whole blood, packed red blood cells, serum and other biosamples, though actual results may differ materially. Closing is anticipated in the third or fourth quarter of 2026, subject to customary conditions, including required FDA licensure and other regulatory authorizations. Vector expects that operating its own collection centers and obtaining related FDA registrations and licensure could expand its accessible market and support its evolution toward a more integrated biospecimen solutions model.
FOXO Technologies (OTC: FOXOD/FOXO) issued a mid‑year 2026 update covering financial results, capital actions and subsidiary performance.
Q1 2026 net revenue was about $5.1 million versus $3.2 million a year earlier, with a reduced operating loss. The company executed a 1:3,000 reverse split, restructured preferred stock, detailed Myrtle and hospital growth, and highlighted Vector BioSource expansion plans.
FOXO Technologies (OTC: FOXO) completed a 1-for-3,000 reverse stock split of its Class A common stock, effective 4:01 p.m. ET on June 30, 2026. Shares begin trading on a split-adjusted basis on July 1, 2026 under temporary symbol FOXOD with CUSIP 351471602.
The symbol is expected to revert to FOXO around July 20, 2026. No fractional shares will be issued; positions will be rounded up to the nearest whole share with no cash paid. FOXO targets a higher share price to support potential OTCQB quotation or a future exchange uplisting.
FOXO Technologies (OTC:FOXO) entered a strategic partnership with LongevityFP Technologies (LFP) via an exclusive license of FOXO’s epigenetics technology, including two patents and related IP. LFP will pay FOXO a 3% royalty on net revenues, capped at $1.3 million.
LFP also receives a ten-year option to acquire majority ownership of FOXO Labs, which holds most epigenetics IP. If exercised, FOXO would own 40% of the resulting epigenetics enterprise. The deal resolves prior matters between the parties and lets FOXO focus on core healthcare services.
FOXO Technologies (OTC: FOXO) said its critical access hospital, Big South Fork Medical Center (Scott County Community Hospital), expanded clinical capabilities on Jan 20, 2026. The hospital added inpatient tele-specialty coverage in cardiology, pulmonology, and nephrology through a partnership with Rural Physicians Group, enabling more specialty evaluation and treatment locally and aiming to reduce patient transfers. The facility also implemented on-site echocardiography services with professional interpretation provided by CompuMed. Management said the additions strengthen local treatment capacity, improve care access, and support a technology-enabled care model intended to help long-term sustainability and increase net revenues.
FOXO Technologies (OTC: FOXO) year-end review (Dec 15, 2025) highlights 2025 operational growth, acquisitions, and financial improvements. Key operating notes: Myrtle Recovery reached a 2025 average daily census of 28 (93% occupancy) with projected 550 admissions vs 195 in 2024 and served patients from 63 of 95 Tennessee counties. Scott County Community Hospital expects >7,000 ER visits, >3,500 outpatient visits and ~300 inpatient stays in 2025. Vector BioSource is expected to generate ~$1M net revenue in 2025. Financials: ~$12M net revenues for nine months ended Sept 30, 2025 and expected to exceed $15M for full year; equity rose from $5.3M (Dec 31, 2024) to $20.2M (Sept 30, 2025); debt reduced from $10.2M to $7.1M. Corporate actions included settling a $2.3M liability and converting ~$3.5M PIK notes to preferred stock. The company formed FOXO Acquisition Corporation and issued Series E preferred (2.5% cash dividend, 5% common stock dividend, secured; nonconvertible). FOXO lost its NYSE American listing in Q3 2025 and says an uplist is possible but not certain.
FOXO Technologies (OTC: FOXO) announced that its behavioral health subsidiary, Myrtle Recovery Centers, was recognized by the Rural Health Association of Tennessee (RHA) at the RHA Annual Conference Awards Luncheon on Dec. 9, 2025.
Myrtle was noted for ongoing community engagement and sharing lessons learned after marking two years of accepting patients in August and serving individuals from 63 of Tennessee’s 95 counties. Leadership said Myrtle operated at capacity for most of 2025 and plans to increase capacity and expand with additional facilities in coming years. Myrtle’s CEO Robert Merritt also presented on substance use disorder treatment and rural behavioral health stigma.
FOXO Technologies (OTCID: FOXO) has completed the acquisition of Vector Biosource Inc., a provider of information, data, and biospecimen sourcing services for biotechnology and pharmaceutical research industries. Vector reported Q2 2025 net revenues of $225,000 ($0.9M annualized).
The acquisition terms include $500,000 in cash, 60,000 shares of Series E Preferred Stock ($1.5M stated value), warrants for $2M of common stock at a 10% premium, and potential additional 80,000 preferred shares ($2M value) based on performance milestones. FOXO will also fund up to $1.2M for Vector's growth initiatives.
FOXO Technologies (OTC: FOXO) has signed a stock purchase agreement to acquire Vector Biosource Inc., a provider of information, data, and biospecimen sourcing services for biotechnology and pharmaceutical research industries. The acquisition terms include $500,000 in cash, 60,000 shares of Series E Preferred Stock ($1.5M stated value), warrants for $2M of common stock, and potential additional preferred shares worth up to $2M based on performance milestones.
Vector reported Q2 2025 revenues of $225,000 ($0.9M annual run rate) and is expected to grow significantly post-acquisition. FOXO has committed to funding up to $1.2M for Vector's growth initiatives. The closing is subject to due diligence completion and other conditions.
FOXO Technologies Inc. (NYSE:FOXO) has announced its delisting from NYSE American due to its stock price falling below the $0.10 minimum requirement. Trading of FOXO's Class A common stock was suspended on NYSE on August 12, 2025.
The Company has successfully secured approval to trade on the Over-the-Counter (OTC) market starting August 13, 2025, maintaining its "FOXO" trading symbol. CEO Seamus Lagan emphasized that despite the delisting, the company's business strategy and economic outlook remain unchanged, with plans to pursue potential acquisitions for growth and consider future NYSE or NASDAQ listing when appropriate.